Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according to NICE.

Daiichi Sankyo has launched its Lixiana product onto the UK market, where it becomes the fourth novel oral anti-coagulant (NOAC) available to treat and prevent clot-related disorders. Lixiana ...

([7]) About the Edoxaban Clinical Research Programme More than 10 studies, more than 100,000 patients worldwide Daiichi Sankyo is committed to expanding scientific knowledge about ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...